From: Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome
Reference | Year of study | Number of FM patients | Number of control individuals | Objective measure | Findings |
---|---|---|---|---|---|
Klein and colleagues [82] | 1992 | 50 | ?HC | Antiserotonin | Increased in FMS |
 |  |  |  | Antiganglioside | Increased in FMS |
 |  |  |  | Antiphospholipid | Increased in FMS |
Klein and Berg [81] | 1995 | 100 | 42 CFS, ?HC | Antiserotonin | Increased in CFS and FMS |
 |  |  |  | Antigangliosides | Increased in CFS and FMS |
 |  |  |  | Antiphospholipid | Increased in CFS and FMS |
Werle and colleagues [83] | 2001 | 203 | 64 | Antiserotonin | Increased |
 |  |  |  | Antithromboplastin | Increased |
 |  |  |  | Antiganglioside | No difference |
 |  |  |  | Gm1 | No difference |
Wilson and colleagues [84] | 1999 | 47 | 16 OA,12 RA, banked sera, 15 myositis, 30 RA, 30 SLE, 30 SSc | Antipolymer antibody | Increased in antipolymer antibodies, higher in severe versus mild |
Nishikai and colleagues [85] | 2001 | 125 | 114 CFS, ?psych, ?CTD | Anti-68/48 kDa | Increased in FMS and CFS |
 |  |  |  | Anti-45 kDa | Increased in FMS and CFS |